An evaluation of the efficacy of eptinezumab in the inpatient management of status migrainosus in comparison to intravenous lignocaine in patients who have failed other therapies

Alfred Health0 sites40 target enrollmentNovember 26, 2021

Overview

No summary available.

Registry

who.int

Start Date

November 26, 2021

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•Aged 18 to 65 inclusive at time of presentation to ED
•\- At least a 1\-year history of migraine with or without aura as per the ICHD\-3 criteria
•\- Age of participant at the time of migraine onset \<50 years old
•\- An acute migraine attack that has persisted for greater than or equal to 72 hours as per the ICHD\-3 criteria for status migrainosus
•\- Ongoing symptoms despite, or contraindication to, triptan and chlorpromazine therapy
•\- In the opinion of the investigator and treating doctor, adequate investigation and consideration has been given for secondary causes of headache prior to enrolment.
•\- Written informed consent obtained from the participant prior to any study\-related procedures

•\- History of hemiplegic migraine, cluster headache or other trigeminal autonomic cephalalgia
•\- Current concomitant diagnosis of a secondary type of headache
•\- Chronic headache with continuous pain lasting more than three weeks
•\- Headache, which in the opinion of the investigator or delegate requires further investigation for secondary causes of headache
•\- Any clinically significant hematologic, endocrine, pulmonary, hepatic, gastrointestinal or neurologic disease
•\- Received an anti\-CGRP product within 6 months
•\- History of known hepatic disease with potential for hepatic function impairment
•\- History of myocardial infarction, stroke, transient ischaemic attack, unstable angina or revascularisation procedure
•\- Cardiac arrythmia
•\- Newly diagnosed or uncontrolled hypertension